@article{7422859e3a6f4e188398825cd8576cba,
title = "Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections",
abstract = "We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after controlling for baseline and postrandomization patient characteristics. This finding provides a novel mechanism of benefit for baricitinib and supports the safety profile of this immunomodulator for the treatment of coronavirus disease 2019.",
keywords = "COVID-19, baricitinib, secondary infections",
author = "Sweeney, {Daniel A.} and Bonifride Tuyishimire and Neera Ahuja and Beigel, {John H.} and Tatiana Beresnev and Cantos, {Valeria D.} and Castro, {Jose G.} and Cohen, {Stuart H.} and Kaitlyn Cross and Dodd, {Lori E.} and Nathan Erdmann and Monica Fung and Varduhi Ghazaryan and George, {Sarah L.} and Grimes, {Kevin A.} and Hynes, {Noreen A.} and Julian, {Kathleen G.} and Sheetal Kandiah and Kim, {Hannah Jang} and Levine, {Corri B.} and Lindholm, {David A.} and Lye, {David C.} and Maves, {Ryan C.} and Oh, {Myoung Don} and Catharine Paules and Rapaka, {Rekha R.} and Short, {Willam R.} and Tomashek, {Kay M.} and Wolfe, {Cameron R.} and Kalil, {Andre C.}",
note = "Publisher Copyright: {\textcopyright} 2023 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America.",
year = "2023",
month = may,
day = "1",
doi = "10.1093/ofid/ofad205",
language = "English (US)",
volume = "10",
journal = "Open Forum Infectious Diseases",
issn = "2328-8957",
publisher = "Oxford University Press",
number = "5",
}